MTVA MetaVia Inc.

Nasdaq metaviatx.com


$ 0.97 $ -0.07 (-6.47 %)    

Friday, 17-Oct-2025 16:54:38 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.9727
$ 1.00
$ 0.97 x 150
$ 1.17 x 1
$ 0.90 - $ 1.02
$ 0.56 - $ 3.16
72,129
na
23.54M
$ 0.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 04-15-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
22 05-20-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-18-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-20-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-21-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 09-14-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HC Wainwright & Co. analyst Andrew S. Fein assumes MetaVia (NASDAQ:MTVA) with a Buy rating and announces Price Target of...

Core News & Articles

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16...

Core News & Articles

Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential ofMetaVia's Oral GPR119 Ag...

Core News & Articles

Top-Line Data Expected in the Fourth Quarter of 2025CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), ...

Core News & Articles

-SEC Filing

Core News & Articles

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_05222025_MTVA_Bautz.pdf

Core News & Articles

Maxim Group analyst Jason McCarthy maintains MetaVia (NASDAQ:MTVA) with a Buy and lowers the price target from $6 to $3.

Core News & Articles

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION